Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints

Friday, May 9, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the population pharmacokinetic and pharmacodynamic modeling of ALG-055009, a novel thyroid hormone receptor beta agonist. The findings reveal a statistically significant correlation between drug exposure and key efficacy endpoints, indicating its potential effectiveness in treating chronic HBV infection. This research may pave the way for better therapeutic strategies.
Price reaction · baseline $4.48 (2025-05-09 close) · hit after-hours · clean, no other ALGS news in the window
day 0 close
+26.8%
day 1 · peak
+32.6%
day 3
+29.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Statistically significant correlation found between exposure and efficacy endpoints.
  • Novel thyroid hormone receptor beta agonist ALG-055009 shows promise.
  • Potential for improved treatment options in chronic HBV infection.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a novel thyroid hormone receptor beta agonist being studied for its efficacy.

What were the key findings of the study?

The study found a statistically significant correlation between ALG-055009 exposure and key efficacy endpoints.

How does ALG-055009 relate to chronic HBV infection?

ALG-055009 shows potential as a treatment option for chronic HBV infection based on its efficacy.

What is pharmacokinetic modeling?

Pharmacokinetic modeling assesses how a drug is absorbed, distributed, metabolized, and excreted in the body.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-055009 thyroid hormone receptor chronic HBV infection pharmacokinetics pharmacodynamics
Last updated: May 9, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →